Performance Status in Cancer: Not Broken, But Time for an Upgrade?
作者信息
Scott Jessica M, Stene Guro, Edvardsen Elisabeth, Jones Lee W
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY.
Weill Cornell Medical College, New York, NY.
出版信息
J Clin Oncol. 2020 Sep 1;38(25):2824-2829. doi: 10.1200/JCO.20.00721. Epub 2020 Jun 25.
Abstract
摘要
相似文献
1
Performance Status in Cancer: Not Broken, But Time for an Upgrade?癌症中的体能状态：未破损，但需要升级了？
J Clin Oncol. 2020 Sep 1;38(25):2824-2829. doi: 10.1200/JCO.20.00721. Epub 2020 Jun 25.
2
Measure Me, Don't Judge Me: Patients as Objective Contributors to Performance Status Measurement.衡量我，而非评判我：患者作为性能状态测量的客观贡献者。
JCO Clin Cancer Inform. 2018 Dec;2:1-4. doi: 10.1200/CCI.18.00029.
3
Interconversion of three measures of performance status: an empirical analysis.三种体能状态测量方法的相互转换：一项实证分析。
Eur J Cancer. 2010 Dec;46(18):3175-83. doi: 10.1016/j.ejca.2010.06.126. Epub 2010 Jul 30.
4
Karnofsky performance status and assessment of global health status.卡诺夫斯基功能状态评分与整体健康状况评估
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):294-5. doi: 10.1097/00042560-199611010-00013.
5
The Palliative Performance Scale #125.姑息治疗表现量表#125。
J Palliat Med. 2006 Aug;9(4):994. doi: 10.1089/jpm.2006.9.994.
6
Neoplastic meningitis-related prognostic significance of the Karnofsky performance status.卡诺夫斯基功能状态对肿瘤性脑膜炎相关的预后意义。
Arch Neurol. 2009 Jan;66(1):74-8. doi: 10.1001/archneurol.2008.506.
7
Use of the Palliative Performance Scale in survival prediction for terminally ill patients in Western Newfoundland, Canada.姑息治疗表现量表在加拿大纽芬兰西部晚期患者生存预测中的应用。
J Palliat Care. 2008 Winter;24(4):282-4.
8
JAMA Oncology Patient Page. Performance Status in Patients With Cancer.《美国医学会杂志·肿瘤学》患者专页。癌症患者的体能状态。
JAMA Oncol. 2015 Oct;1(7):998. doi: 10.1001/jamaoncol.2015.3113.
9
Karnofsky Performance Scale (KPS) or Physical Performance Test (PPT)? That is the question.卡氏行为状态量表（KPS）还是体能测试（PPT）？这是个问题。
Crit Rev Oncol Hematol. 2011 Feb;77(2):142-7. doi: 10.1016/j.critrevonc.2010.01.015. Epub 2010 Feb 24.
10
Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer.患者自身、护士及肿瘤学家评估的体能状态在晚期非小细胞肺癌中的预后价值
Br J Cancer. 2001 Nov 30;85(11):1634-9. doi: 10.1054/bjoc.2001.2162.
引用本文的文献
1
Addressing the evidence gap: exploratory insights into dual challenges of mild cognitive impairment and hematologic cancer in older adults through mixed methods and social listening study.填补证据空白：通过混合方法和社会倾听研究对老年人轻度认知障碍和血液系统癌症双重挑战的探索性见解
Eur Geriatr Med. 2025 Sep 16. doi: 10.1007/s41999-025-01292-y.
2
Eligibility criteria in phase 3 randomized controlled trials in gastric cancer.胃癌三期随机对照试验的纳入标准。
Gastric Cancer. 2025 Sep 11. doi: 10.1007/s10120-025-01653-3.
3
Measures of physical functioning in adults with brain tumor associated with functional outcomes: A scoping review.脑肿瘤成人患者身体功能与功能结局的相关测量：一项范围综述
Neurooncol Pract. 2025 Mar 26;12(4):571-584. doi: 10.1093/nop/npaf036. eCollection 2025 Aug.
4
Predicting Tolerance to Anthracycline Chemotherapy Using Electrocardiogram-Based Artificial Intelligence in Sarcoma.使用基于心电图的人工智能预测肉瘤患者对蒽环类化疗的耐受性
Mayo Clin Proc Digit Health. 2025 Jul 4;3(3):100247. doi: 10.1016/j.mcpdig.2025.100247. eCollection 2025 Sep.
5
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009-2023).导致美国食品药品监督管理局药物批准的癌症临床试验中的性能状态资格要求和入组特征（2009 - 2023年）
Eur J Cancer. 2025 Jul 25;225:115589. doi: 10.1016/j.ejca.2025.115589. Epub 2025 Jun 26.
6
Exercise Testing Characteristics, Safety, and Quality in Patients with Cancer: A Systematic Review.癌症患者的运动测试特征、安全性及质量：一项系统综述
Mayo Clin Proc Innov Qual Outcomes. 2025 Jun 11;9(4):100628. doi: 10.1016/j.mayocpiqo.2025.100628. eCollection 2025 Aug.
7
Navigating challenging patient factors in systemic therapy for head and neck cancer.应对头颈癌全身治疗中具有挑战性的患者因素。
Oncologist. 2025 May 8;30(5). doi: 10.1093/oncolo/oyaf035.
8
Does frailty modulate the predictive value of performance status in older adults living with cancer?衰弱是否会调节癌症老年患者体能状态的预测价值？
Res Sq. 2025 Apr 15:rs.3.rs-6285336. doi: 10.21203/rs.3.rs-6285336/v1.
9
Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma.患者报告结局对达雷妥尤单抗治疗的多发性骨髓瘤生存及不良事件的预测和预后意义
Eur J Haematol. 2025 Jun;114(6):1020-1031. doi: 10.1111/ejh.14410. Epub 2025 Mar 14.
10
Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignancies.胃肠道恶性肿瘤患者既往存在的心血管疾病与氟尿嘧啶化疗给药的相关性。
BMJ Oncol. 2024 Aug 8;3(1):e000323. doi: 10.1136/bmjonc-2024-000323. eCollection 2024.
本文引用的文献
1
Association of Daily Step Count and Step Intensity With Mortality Among US Adults.美国成年人的日常步数和步频与死亡率的关系。
JAMA. 2020 Mar 24;323(12):1151-1160. doi: 10.1001/jama.2020.1382.
2
Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer.癌症患者诊断后心肺适能与特定原因死亡率的关联。
Eur Heart J Qual Care Clin Outcomes. 2020 Oct 1;6(4):315-322. doi: 10.1093/ehjqcco/qcaa015.
3
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.2009-2018 年新药推向市场所需的研发投资估算。
JAMA. 2020 Mar 3;323(9):844-853. doi: 10.1001/jama.2020.1166.
4
Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis.医务人员体能状态评估中绩效评估的组内可靠性：更新的系统评价和荟萃分析。
Support Care Cancer. 2020 May;28(5):2071-2078. doi: 10.1007/s00520-019-05261-7. Epub 2020 Jan 3.
5
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
6
Multisystem Toxicity in Cancer: Lessons from NASA's Countermeasures Program.癌症多系统毒性：来自 NASA 对抗措施计划的教训。
Cell. 2019 Nov 14;179(5):1003-1009. doi: 10.1016/j.cell.2019.10.024.
7
Need for Multidisciplinary Research and Data-Driven Guidelines for the Cardiovascular Care of Patients With Cancer.癌症患者心血管护理的多学科研究及数据驱动指南的必要性。
JAMA. 2019 Nov 12;322(18):1775-1776. doi: 10.1001/jama.2019.17415.
8
Innovation and Access at the Mercy of Payment Policy: The Future of Chimeric Antigen Receptor Therapies.创新与可及性受制于支付政策：嵌合抗原受体疗法的未来
J Clin Oncol. 2020 Feb 10;38(5):384-387. doi: 10.1200/JCO.19.01691. Epub 2019 Nov 1.
9
Using Smartphones to Capture Novel Recovery Metrics After Cancer Surgery.使用智能手机捕获癌症手术后的新型康复指标。
JAMA Surg. 2020 Feb 1;155(2):123-129. doi: 10.1001/jamasurg.2019.4702.
10
Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients.可穿戴活动监测器用于评估晚期癌症患者的功能状态并预测临床结局。
NPJ Digit Med. 2018 Jul 5;1:27. doi: 10.1038/s41746-018-0032-6. eCollection 2018.
Zotero 插件